Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action

被引:245
作者
Casini, Angela [1 ]
Hartinger, Christian [2 ]
Gabbiani, Chiara [1 ]
Mini, Enrico [3 ]
Dyson, Paul J. [2 ]
Keppler, Bernard K. [4 ]
Messori, Luigi [1 ]
机构
[1] Univ Florence, Dept Chem, I-50019 Florence, Italy
[2] Ecole Polytech Fed Lausanne, Inst Sci Ingn Chim, CH-1015 Lausanne, Switzerland
[3] Univ Florence, Dept Pharmacol, I-50019 Florence, Italy
[4] Univ Vienna, Inst Inorgan Chem, A-1090 Vienna, Austria
关键词
gold(III) complexes; anticancer agents; proteins; ESI mass spectrometry; mechanism of action;
D O I
10.1016/j.jinorgbio.2007.11.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Gold(III) compounds constitute an emerging class of biologically active substances, of special interest as potential anticancer agents. During the past decade a number of structurally diverse gold(III) complexes were reported to be acceptably stable under physiological-like conditions and to manifest very promising cytotoxic effects against selected human tumour cell lines, making them good candidates as anti-tumour drugs. Some representative examples will be described in detail. There is considerable interest in understanding the precise biochemical mechanisms of these novel cytotoxic agents. Based on experimental evidence collected so far we hypothesize that these metallodrugs, at variance with classical platinum(II) drugs, produce in most cases their growth inhibition effects through a variety of "DNA-independent" mechanisms. Notably, strong inhibition of the selenoenzyme thioredoxin reductase and associated disregulation of mitochondrial functions were clearly documented in some selected cases, thus providing a solid biochemical basis for the pronounced proapoptotic effects. These observations led us to investigate in detail the reactions of gold(III) compounds with a few model proteins in order to gain molecular-level information on the possible interaction modes with possible protein targets. Valuable insight on the formation and the nature of gold-protein adducts was gained through ESI MS (electrospray ionization mass spectrometry) and spectrophotometric studies of appropriate model systems as it is exemplified here by the reactions of two representative gold(III) compounds with cytochrome c and ubiquitin. The mechanistic relevance of gold(III)-induced oxidative protein damage and of direct gold coordination to protein sidechains is specifically assessed. Perspectives for the future of this topics are briefly outlined. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:564 / 575
页数:12
相关论文
共 52 条
[1]
Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichlolro(o-phenanthroline)gold(III) chloride [J].
Abbate, F ;
Orioli, P ;
Bruni, B ;
Marcon, G ;
Messori, L .
INORGANICA CHIMICA ACTA, 2000, 311 (1-2) :1-5
[2]
Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro [J].
Aldinucci, Donatella ;
Lorenzon, Debora ;
Stefani, Luigi ;
Giovagnini, Lorena ;
Colombatti, Alfonso ;
Fregona, Dolores .
ANTI-CANCER DRUGS, 2007, 18 (03) :323-332
[3]
Physiological functions of thioredoxin and thioredoxin reductase [J].
Arnér, ESJ ;
Holmgren, A .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20) :6102-6109
[4]
Targeting the mitochondrial cell death pathway with gold compounds [J].
Barnard, Peter J. ;
Berners-Price, Susan J. .
COORDINATION CHEMISTRY REVIEWS, 2007, 251 (13-14) :1889-1902
[5]
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines [J].
Bergamo, A ;
Stocco, G ;
Gava, B ;
Cocchietto, M ;
Alessio, E ;
Serli, B ;
Iengo, E ;
Sava, G .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02) :725-732
[6]
Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes [J].
Buckley, RG ;
Elsome, AM ;
Fricker, SP ;
Henderson, GR ;
Theobald, BRC ;
Parish, RV ;
Howe, BP ;
Kelland, LR .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (26) :5208-5214
[7]
Gold(III) compounds as potential antitumor agents: cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes [J].
Carotti, S ;
Guerri, A ;
Mazzei, T ;
Messori, L ;
Mini, E ;
Orioli, P .
INORGANICA CHIMICA ACTA, 1998, 281 (01) :90-94
[8]
Ruthenium anticancer drugs and proteins:: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c [J].
Casini, Angela ;
Mastrobuoni, Guido ;
Terenghi, Mattia ;
Gabbiani, Chiara ;
Monzani, Enrico ;
Moneti, Gloriano ;
Casella, Luigi ;
Messori, Luigi .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2007, 12 (08) :1107-1117
[9]
ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes [J].
Casini, Angela ;
Mastrobuoni, Guido ;
Ang, Wee Han ;
Gabbiani, Chiara ;
Pieraccini, Giuseppe ;
Moneti, Gloriano ;
Dyson, Paul J. ;
Messori, Luigi .
CHEMMEDCHEM, 2007, 2 (05) :631-+
[10]
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme [J].
Casini, Angela ;
Mastrobuoni, Guido ;
Temperini, Claudia ;
Gabbiani, Chiara ;
Francese, Simona ;
Moneti, Gloriano ;
Supuran, Claudiu T. ;
Scozzafava, Andrea ;
Messori, Luigi .
CHEMICAL COMMUNICATIONS, 2007, (02) :156-158